3 hours Celldex Therapeutics (NASDAQ:CLDX) Coverage Initiated by Analysts at The Goldman Sachs Group MarketBeat
The Goldman Sachs Group initiated coverage on Celldex Therapeutics in a report on Monday. They set a “neutral” rating and a $45.00 price target for the company.
Goldman Sachs (GS) · Nasdaq 100